Robotic surgery in urology: facts and reality. What are the real advantages of robotic approaches for prostate cancer patients?Ploussard, GuillaumeCurrent Opinion in Urology: March 2018 - Volume 28 - Issue 2 - p 153–158 doi: 10.1097/MOU.0000000000000470 ROBOTIC SURGERY IN UROLOGY: FACTS AND REALITY: Edited by Alexandre de la Taille and Jim C. Hu Buy Abstract Author InformationAuthors Article MetricsMetrics Purpose of review Despite the worldwile increasing use of robotic assistance for oncology surgery, no level 1 evidence-based benefit favoring robot-assisted radical prostatectomy (RARP) versus pure laparoscopic or open approaches has been demonstrated. We aimed to perform an update of the available evidence by evaluating most recent 2016–2017 data. Recent findings Population-based and prospective nonrandomized studies and one phase III randomised trial have been recently published. Early results from the phase III trial suggested that RARP led to similar early functional and oncologic outcomes compared with open radical prostatectomy. Shorter operative time, hospital stay, and lower complications rate and blood loss were reported in RARP group compared with open radical prostatectomy group. Population-based data did not demonstrate any benefit from one approach over another in terms of functional and oncologic outcomes. Robot assistance is predictive for improved potency recovery in organ-confined tumor in one large prospective trial. Main limitations, different among studies, were lack of randomization or single operator cohorts, short-term follow-up, and absence of confounding factors analysis. Summary Robotic assistance seems to confer better results than open radical prostatectomy procedures in terms of intra- and immediate postoperative parameters (operative time, blood loss and hospital stay). Clear advantages of one technique over another on robust functional or oncologic endpoints remain unproven. Division of Urology Saint Jean Languedoc Hospital, and Institut Universitaire du Cancer Oncopole, Toulouse, France Correspondence to Dr Guillaume Ploussard, Division of Urology Saint Jean Languedoc Hospital, and Institut Universitaire du Cancer Oncopole, 20, route de Revel, 31500, Toulouse, France. Tel: +33 5 61 54 90 45; fax: +33 5 62 47 19 11; e-mail: firstname.lastname@example.org Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.